Clinical Trial Update: A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009) [Phase 1]

View source ↗

Summary

Phase 1 trial update for Omarigliptin (MK-3102) in participants with impaired renal function has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Insufficiency
• Type 2 Diabetes Mellitus

Drugs mentioned

• Omarigliptin (omarigliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Renal Insufficiency, Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2015-12-03